Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 10/20 | 0.50 |
| ▸ | CHUK | O15111 | 8/20 | 0.50 |
| ▸ | IKBKG | Q9Y6K9 | 8/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939477 | 0.81 | CDC7 (0.60) | CYP19A1IKBKBCHUKIKBKGKDM1A | |
| SCHEMBL20576209 | 0.79 | CYP19A1 (0.46) | CYP19A1IKBKBCHUKIKBKGKDM1A | |
| SCHEMBL3962182 | 0.78 | FGFR1 (0.40) | CYP19A1IKBKBCHUKIKBKGMAPK9 | |
| SCHEMBL3053763 | 0.77 | CA2 (0.42) | CDC7APPCCNT1CDK2CDK9 | |
| SCHEMBL29415478 | 0.76 | CYP19A1 (0.60) | CYP19A1IKBKBCHUKIKBKGKDM1A | |
| SCHEMBL403651 | 0.76 | CYP19A1 (0.60) | CYP19A1IKBKBCHUKIKBKGKDM1A | |
| SCHEMBL1337994 | 0.76 | MEN1 (0.34) | CYP19A1IKBKBCHUKIKBKGMEN1 | |
| SCHEMBL16200263 | 0.75 | CYP19A1 (0.52) | CYP19A1IKBKBCHUKIKBKGKDM1A | |
| SCHEMBL2986306 | 0.75 | IKBKB (0.48) | CYP19A1IKBKBCHUKIKBKGKDM1A | |
| SCHEMBL6230863 | 0.75 | CYP19A1 (0.59) | CYP19A1IKBKBCHUKIKBKGKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113382991-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| CN-101309918-B | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI | 2010-12-29 | — | — | CN | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| EP-1989200-B1 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7547691-B2 | [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | ELI LILLY AND COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
| CN-101309918-A | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI (US) | 2008-11-19 | — | — | CN | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | CYP19A1 2257/4885IKBKB 2/4885CHUK 3/4885 |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | NFKBIA, IKBKB, IKBKG | CYP19A1 1251/4885IKBKB 2/4885CHUK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.